Valuation: Voyageur Pharmaceuticals Ltd.

Market Cap 33.95M 24.09M 21.14M 19.87M 18.17M 2.31B 34.2M 239M 92.54M 1.18B 90.45M 88.47M 3.81B P/E 2024
-5.24x
P/E 2025 -7.5x
Enterprise Value 33.72M 23.92M 21M 19.74M 18.05M 2.29B 33.97M 237M 91.91M 1.17B 89.84M 87.87M 3.79B EV / Sales 2024
-
EV / Sales 2025 2,423,581,172x
Free-Float
93.07%
Yield 2024 *
-
Yield 2025 -
08-10 Voyageur Pharmaceuticals Ltd. Advances Mueller Iodine Extraction Process with 99.8% Purity Results and Planned Field Pilot Testing CI
07-24 Voyageur Pharmaceuticals Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2026 CI
06-18 Voyageur Pharmaceuticals Evaluates Three Locations in the United States for Integrated Iodine and Barium Contrast Media Manufacturing Facility CI
06-10 Voyageur Pharmaceuticals Ltd Submits Multi-Year Area-Based Exploration Permit Application for Bulk Sampling and Feasibility Support At Frances Creek Barite Project CI
06-04 Voyageur Pharmaceuticals Ltd. announced that it has received CAD 5.005278 million in funding CI
04-30 Voyageur Pharmaceuticals Ltd. announced that it expects to receive CAD 10 million in funding CI
04-30 Voyageur Pharmaceuticals Ltd. cancelled the transaction announced on March 24, 2026 CI
04-24 Voyageur Pharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended February 28, 2026 CI
03-27 Voyageur Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended November 30, 2025 CI
03-26 Voyageur Pharmaceuticals Ltd. Auditor Raises 'Going Concern' Doubt CI
03-23 Voyageur Pharmaceuticals Ltd. announced that it expects to receive CAD 7.5 million in funding CI
03-04 Voyageur Pharmaceuticals Ltd. Announces Independent Laboratory Test Results for Its Barium Sulfate Active Pharmaceutical Ingredient CI
02-23 Voyageur Pharmaceuticals Announces Collaboration with Bayer Aktiengesellschaft CI
1 day-18.58%
1 week+15.00%
Current month-25.81%
1 month-23.33%
3 months-8.00%
6 months-12.38%
Current year-29.29%
1 week 0.05
Extreme 0.0501
0.12
1 month 0.05
Extreme 0.0501
1.03
Current year 0.01
Extreme 0.014
1.03
1 year 0
Extreme 0.0033
1.03
3 years 0
Extreme 0.0005
1.03
5 years 0
Extreme 0.0005
1.03
10 years 0
Extreme 0.0005
1.03
Manager TitleAgeSince
Chief Executive Officer - 2019-06-30
Director of Finance/CFO - 2022-08-16
Chief Tech/Sci/R&D Officer - 2024-09-16
Director TitleAgeSince
Director/Board Member - 2017-12-05
Director/Board Member - 2019-06-30
Chairman - 2025-04-29
Change 5-day change 1-year change 3-year change Capi.($)
-18.58%+15.00% - - 24.09M
-1.64%+1.16%+54.09%+109.07% 1,026B
-0.01%+0.71%+52.44%+67.71% 649B
-0.05%+0.98%+19.08%+73.55% 468B
-0.43%+0.08%+39.09%+44.86% 352B
+0.78%+2.26%+21.27%+28.26% 271B
-0.71%-0.56%+10.25%+10.41% 256B
-1.01%+7.90%+41.59%+51.70% 220B
-0.85%+2.50%+32.32%+101.80% 188B
-1.37%-10.78%-32.92%-60.88% 170B
Average -1.85%+1.26%+26.36%+47.38% 399.9B
Weighted average by Cap. +0.31%+1.26%+36.17%+65.71%

Financials

2024 2025
Net sales - 0.01 0.01 0.01 0.01 0.01 0.79 0.01 0.08 0.03 0.4 0.03 0.03 1.31
Net income -1.71M -1.21M -1.06M -999K -914K -116M -1.72M -12M -4.65M -59.15M -4.55M -4.45M -192M -3.53M -2.51M -2.2M -2.07M -1.89M -240M -3.56M -24.84M -9.63M -122M -9.41M -9.21M -397M
Net Debt -113K -79.91K -70.13K -65.93K -60.27K -7.65M -113K -792K -307K -3.9M -300K -293K -12.65M -231K -164K -144K -135K -123K -15.67M -232K -1.62M -628K -7.99M -614K -601K -25.9M
Logo Voyageur Pharmaceuticals Ltd.
Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine active pharmaceutical ingredients (API) and imaging contrast agents for medical radiology. It focuses on vertically integrating the barium and iodine contrast markets. In addition, Voyageur is pursuing the development of new endo fullerene drugs. Its products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. At the core of its operations, the Company also owns a 100% interest in the Frances Creek Project, which boasts a mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.
Employees
-
Date Price Change Volume
26-09-23 US$0.0920 -18.58% 52,000
26-09-22 US$0.1130 +10.68% 50,000
26-09-21 US$0.1021 +0.10% 102,000
26-09-18 US$0.1020 -6.42% 104,000
26-09-17 US$0.1090 +36.25% 105,000

Annual profits - Rate of surprise